• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Video

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

Transcript

With the first 2 anticancer biosimilars having recently entered the market and more waiting to enter, do you think biosimilars will start to play a bigger role in oncology?

I think absolutely. They already have. What we’re seeing on the biosimilar front is actually a greater adoption than most folks thought initially for the non-supportive chemotherapy agents like Avastin, Herceptin, Rituxan. We were thinking maybe a 10% adoption right away. It’s looking more like it’s 15% to 20%. So, I think you’re going to see that trend continue. Biosimilars are going to be here to stay in my opinion and it’s going to be a great opportunity for community oncology.

Related Videos
Coral Omene, MD, PhD, sitting for a vieo interview
Dr Ola Landgren
David Awad, PharmD, BCOP
Gordon Crofoot, MD, PA
Jaime Almandoz, MD, MBA
Screenshot of Coral Omene, MD, PhD
Dr Brian Slomovitz
2 experts in this video
2 experts in this video
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.